Literature DB >> 1988793

Methadone dosage and retention of patients in maintenance treatment.

J R Caplehorn1, J Bell.   

Abstract

Retention of patients in methadone treatment was studied in a cohort of 238 heroin addicts who entered maintenance programmes between February 1986 and August 1987. All subjects had been assessed at a centralised unit and referred to one of two other units for maintenance. Of the ten client characteristics that we analysed, three--a history of imprisonment, a history of dependence on barbiturates or benzodiazepines and employment status at entry--were included with "clinic" and maximum dose of methadone in the Cox regression models. Allowing for the other four variables, the maximum daily dose of methadone dispensed during the study period was a highly significant predictor of retention (P less than 0.00001). With maximum dose stratified into three levels--less than 60 mg, 60-79 mg, 80+ mg--and with the lowest stratum used as the baseline, the relative risk (RR) of leaving treatment was halved (RR 0.47, 95% confidence interval [CI] 0.33-0.67) for subjects receiving 60-79 mg, and halved again (RR 0.21, 95% CI 0.12-0.38) for those who received 80+ mg. Clinic dosage policies contribute significantly to retention in methadone maintenance treatment. Clinics need to develop dosage policies in negotiation with individual patients.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1988793

Source DB:  PubMed          Journal:  Med J Aust        ISSN: 0025-729X            Impact factor:   7.738


  17 in total

1.  Policy progress for physician treatment of opiate addiction.

Authors:  Joseph O Merrill
Journal:  J Gen Intern Med       Date:  2002-05       Impact factor: 5.128

2.  Superior methadone treatment outcome in Hmong compared with non-Hmong patients.

Authors:  Gavin Bart; Qi Wang; James S Hodges; Chris Nolan; Gregory Carlson
Journal:  J Subst Abuse Treat       Date:  2012-01-28

Review 3.  Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence.

Authors:  Chin B Eap; Thierry Buclin; Pierre Baumann
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

4.  Methadone dose at the time of release from prison significantly influences retention in treatment: implications from a pilot study of HIV-infected prisoners transitioning to the community in Malaysia.

Authors:  Jeffrey A Wickersham; Muhammad Muhsin Zahari; Marwan M Azar; Adeeba Kamarulzaman; Frederick L Altice
Journal:  Drug Alcohol Depend       Date:  2013-02-13       Impact factor: 4.492

5.  Premature discharge from methadone treatment: patient perspectives.

Authors:  Heather Schacht Reisinger; Robert P Schwartz; Shannon Gwin Mitchell; James A Peterson; Sharon M Kelly; Kevin E O'Grady; Erica A Marrari; Barry S Brown; Michael H Agar
Journal:  J Psychoactive Drugs       Date:  2009-09

Review 6.  Methadone maintenance treatment in opiate dependence: a review.

Authors:  M Farrell; J Ward; R Mattick; W Hall; G V Stimson; D des Jarlais; M Gossop; J Strang
Journal:  BMJ       Date:  1994-10-15

7.  Inverse odds ratio-weighted estimation for causal mediation analysis.

Authors:  Eric J Tchetgen Tchetgen
Journal:  Stat Med       Date:  2013-06-07       Impact factor: 2.373

8.  Predictors of attrition from a national sample of methadone maintenance patients.

Authors:  Michael Mancino; Geoffrey Curran; Xiaotong Han; Elise Allee; Keith Humphreys; Brenda M Booth
Journal:  Am J Drug Alcohol Abuse       Date:  2010-05       Impact factor: 3.829

9.  Intermittent marijuana use is associated with improved retention in naltrexone treatment for opiate-dependence.

Authors:  Wilfrid Noel Raby; Kenneth M Carpenter; Jami Rothenberg; Adam C Brooks; Huiping Jiang; Maria Sullivan; Adam Bisaga; Sandra Comer; Edward V Nunes
Journal:  Am J Addict       Date:  2009 Jul-Aug

10.  Does naltrexone treatment lead to depression? Findings from a randomized controlled trial in subjects with opioid dependence.

Authors:  Angela J Dean; John B Saunders; Rod T Jones; Ross M Young; Jason P Connor; Bruce R Lawford
Journal:  J Psychiatry Neurosci       Date:  2006-01       Impact factor: 6.186

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.